publication date: Apr. 18, 2016

Stand Up To Cancer Debuts Catalyst Research Program With Merck, BMS and Genentech 

 

Stand Up To Cancer announced Catalyst, a program that will use funding and materials from the pharmaceutical, biotechnology, diagnostic and medical devices industries to accelerate research on cancer prevention, detection and treatment.

Founding collaborator Merck; and Bristol-Myers Squibb, and Genentech, a member of the Roche Group, will serve as charter supporters.

“The Catalyst program is a perfect fit with the SU2C mission of accelerating the pace of groundbreaking translational research that provides new therapies to patients quickly,” said Sung Poblete, president and chief executive officer of SU2C. “This will be a nimble program that will help speed up the rate at which we discover what works.”

Under the SU2C Catalyst program, companies like Merck, Bristol-Myers Squibb and Genentech will donate funds to support collaborative research studies using products the companies will provide, such as new pharmaceutical compounds that they are developing or approved agents that can be investigated for other uses.

Through the American Association for Cancer Research, SU2C will issue a request for proposals based on each company’s commitment of funding and materials such as drugs and diagnostic tests. The RFP will lay out the compounds that will be available, the research emphasis, the estimated number of projects that will be supported, and funding available.

The SU2C Catalyst program will be overseen by an executive committee chaired by Nobel laureate Phillip Sharp, chair of the SU2C Scientific Advisory Committee and institute professor at the Koch Institute for Integrated Cancer Research at MIT.

Continue reading 42-15 Stand Up To Cancer Debuts Catalyst Research Program With Merck, BMS and Genentech
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.